Table 12.8
Adjusted Graft Survival, Deceased Donor Lung Transplants
Survival at 3 Months, 1 Year, 3 Years, and 5 Years

	3 Months			1 Year			3 Years			5 Years		
	(Tx 2003 - 2004)			(Tx 2003 - 2004)			(Tx 2001 - 2004)			(Tx 1999 - 2004)		
	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.
Total												
All	2,218	92.7%	0.6%	2,218	83.8%	0.8%	4,280	64.5%	0.9%	6,083	48.3%	0.9%
Age at Tx												
<1 Year	8	54.1%	23.1%	8	54.1%	23.1%	13	60.0%	13.6%	20	57.3%	12.8%
1-5 Years	3	80.0%	15.2%	3	80.0%	15.2%	11	58.1%	16.6%	17	28.2%	13.3%
6-10 Years	15	94.5%	5.3%	15	88.9%	8.0%	27	72.0%	12.5%	44	66.9%	9.3%
11-17 Years	64	94.5%	2.8%	64	81.9%	5.1%	105	57.6%	6.7%	152	35.5%	6.2%
18-34 Years	297	92.9%	1.7%	297	85.1%	2.8%	558	61.1%	3.4%	791	45.9%	3.2%
35-49 Years	421	94.2%	1.1%	421	86.3%	1.7%	888	67.2%	1.9%	1,321	52.5%	1.9%
50-64 Years	1,250	92.3%	0.8%	1,250	83.4%	1.2%	2,435	65.0%	1.3%	3,425	48.1%	1.4%
65+ Years	160	92.1%	2.1%	160	77.7%	3.4%	243	58.0%	4.4%	313	41.5%	4.7%
Recipient Ethnicity/Race												
White	1,918	92.7%	0.6%	1,918	83.6%	0.9%	3,748	64.4%	1.0%	5,369	48.6%	1.0%
African American	160	94.8%	1.6%	160	85.7%	2.7%	309	66.2%	3.3%	428	45.3%	3.7%
Hispanic/Latino	103	89.6%	2.8%	103	81.1%	3.7%	166	59.3%	4.7%	215	50.0%	4.9%
Asian	27	94.3%	3.9%	27	91.4%	4.7%	41	70.9%	9.7%	48	53.4%	10.9%
Other/Multi-race	8	89.5%	9.1%	8	89.5%	9.1%	14	74.2%	10.6%	21	35.2%	13.6%
Unknown	2	+	+	2	+	+	2	+	+	2	+	+
Recipient Gender												
Female	1,071	92.6%	0.8%	1,071	83.4%	1.2%	2,136	63.2%	1.3%	3,034	47.8%	1.4%
Male	1,147	92.8%	0.8%	1,147	84.1%	1.1%	2,144	65.9%	1.2%	3,049	48.9%	1.3%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
(+) = Values not determined due to insufficient follow-up. (-) = Values not determined since there were no transplants in the category.
Cohorts are transplants performed during the years listed at the top of the table.
Graft survival follows individual transplants until graft failure. Counts for patient and graft survival are different because a patient may have more than one transplant for a type of organ.
Center volume = Center's yearly transplants performed during the base period, based on lung and heart-lung transplants.
Multi-organ transplants are excluded.
Survival rates are adjusted to the characteristics of the 3 month and 1 year cohort. See Technical Notes for details.

Table 12.8 (Continued)
Adjusted Graft Survival, Deceased Donor Lung Transplants
Survival at 3 Months, 1 Year, 3 Years, and 5 Years

	3 Months			1 Year			3 Years			5 Years		
	(Tx 2003 - 2004)			(Tx 2003 - 2004)			(Tx 2001 - 2004)			(Tx 1999 - 2004)		
	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.
Total												
All	2,218	92.7%	0.6%	2,218	83.8%	0.8%	4,280	64.5%	0.9%	6,083	48.3%	0.9%
Primary Diagnosis												
Emphysema/COPD	852	94.7%	0.8%	852	87.2%	1.2%	1,729	67.7%	1.5%	2,519	49.4%	1.6%
Cystic Fibrosis	367	93.8%	1.4%	367	83.0%	2.5%	680	66.2%	2.6%	980	47.0%	2.7%
Idiopathic Pulmonary Fibrosis	514	89.8%	1.4%	514	79.2%	1.9%	893	59.1%	2.1%	1,178	45.8%	2.2%
Alpha-1-Antitrypsin Deficiency	126	92.6%	2.4%	126	89.2%	2.8%	290	66.7%	3.3%	428	50.6%	3.6%
Primary Pulmonary Hypertension	79	81.8%	4.5%	79	74.5%	5.2%	166	60.6%	4.3%	243	50.2%	4.3%
Congenital Disease	18	100.0%	0.0%	18	88.8%	7.3%	36	52.8%	10.8%	64	47.8%	7.7%
Other	238	92.2%	1.8%	238	78.7%	2.8%	460	61.9%	2.8%	641	53.9%	2.6%
Unknown	24	79.1%	8.1%	24	70.8%	9.1%	26	69.4%	8.8%	30	52.2%	14.8%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
(+) = Values not determined due to insufficient follow-up. (-) = Values not determined since there were no transplants in the category.
Cohorts are transplants performed during the years listed at the top of the table.
Graft survival follows individual transplants until graft failure. Counts for patient and graft survival are different because a patient may have more than one transplant for a type of organ.
Center volume = Center's yearly transplants performed during the base period, based on lung and heart-lung transplants.
Multi-organ transplants are excluded.
Survival rates are adjusted to the characteristics of the 3 month and 1 year cohort. See Technical Notes for details.